PeptideGlobal

Ozempic in Jamaica cleared for distribution as Tufton promises cheaper generics

Health Minister Christopher Tufton says Ozempic is approved for distribution in Jamaica, with other obesity drugs and generics hoped for next year and National Health Fund access under consideration. No price, supplier or date was given.

Illustration for the story: Ozempic in Jamaica cleared for distribution as Tufton promises cheaper generics

Illustration by Peptide Global, not a picture of the place in the story.

The short of itJamaica's health minister says Ozempic is approved for distribution, with other obesity drugs and cheaper generics hoped for next year through pharmacies.

Ozempic in Jamaica has been approved for distribution, Health and Wellness Minister Christopher Tufton said on 12 November, as the government widens treatment options for obesity. He gave the news at the launch of a ministry Lifestyle Clinic at the Sandy Bay Health Centre in Hanover. Tufton said other branded obesity medicines and their generic copies could follow, sold through pharmacies, and that access through the National Health Fund would be considered. He gave no price, supplier or launch date.

What the minister announced

The account of the speech, published by The Gleaner from the Jamaica Information Service, says Ozempic has been approved for distribution on the island. It does not name the body that granted the approval or say which uses the approval of Ozempic in Jamaica covers. Ozempic is Novo Nordisk's weekly semaglutide injection. In most markets its licensed use is type 2 diabetes, while weight management is sold under the separate Wegovy brand, so the exact wording of the Jamaican approval matters for how doctors may prescribe it. Tufton described the drug as a treatment that controls blood sugar and supports weight loss by reducing appetite and slowing digestion.

Tufton said other branded medicines for obesity are under consideration. "We hope that by next year, they will be approved, and also the generic equivalent to those," he said, without naming the products. In the same remarks he said that over the next quarter or so the drugs should become available, with the generic versions as the cheaper choice, and that the medicines would be sold through pharmacies. The two timelines do not fit neatly together: one points to next year for further approvals, the other to roughly three months for availability. The ministry has not published a list of products, prices or dates, so it is not yet clear which medicines will reach pharmacies first or at what cost.

ItemDetail
Announced byChristopher Tufton, Minister of Health and Wellness
Date12 November 2026
PlaceSandy Bay Health Centre, Hanover
Product approvedOzempic, semaglutide, made by Novo Nordisk
Approving body and usesNot stated in the report
Other obesity medicinesUnder consideration, approval hoped for next year
GenericsExpected to follow at lower prices
Public fundingNational Health Fund access to be considered
Price and supplierNot disclosed

Ending the informal trade

Before the approval, people seeking these drugs in Jamaica bought them informally, often abroad and at inflated prices, the minister said. "What used to happen in the past is that it was a black market," Tufton said, adding that people bought the drugs in Miami and elsewhere and resold them at higher cost. Informal supply carries risks beyond price. Pens carried in luggage may be stored badly in transit, and fake weight loss pens have turned up in other markets, including a large counterfeit pen haul in Birmingham in the United Kingdom last month. A licensed product sold through pharmacies gives patients a traceable source and a pharmacist who can check the prescription.

A licensed product sold through pharmacies gives patients a traceable source and a pharmacist who can check the prescription.

Cost is the other half of the problem. Tufton said access through the National Health Fund, the public body that subsidises medicines for chronic illness in Jamaica, would be considered, but he did not say whether semaglutide would be listed or for which patients. Without a subsidy, patients will pay the pharmacy price, which has not been disclosed. Generic semaglutide is already sold in some countries where Novo Nordisk's main patent has lapsed, as the semaglutide patent expiry map on this site shows, and those copies are priced below the brand. Whether such copies can be registered in Jamaica depends on local patent and regulatory status, which the report did not address.

The Lifestyle Clinic model

The approval was announced at the opening of a clinic, not a pharmacy, and the setting shows how the ministry wants the drugs used. The Lifestyle Clinic at Sandy Bay is aimed at people whose health is at risk because of obesity. Doctors will refer patients after a medical assessment, and the clinic will offer support from psychologists, nutritionists, physical activity specialists and social workers to help people change daily habits and lower their risk of serious illness. That team approach matches the way many health systems try to use weight loss medicines, alongside diet, activity and follow up rather than in place of them. The report did not say how many patients the clinic can take.

Tufton was careful not to oversell the medicines. "That's part of controlling obesity. It's not the full picture," he said, adding that he was not prescribing one solution to the problem. Managing obesity, he argued, needs proper nutrition, exercise and medical supervision. For Ozempic in Jamaica this framing has practical consequences. If clinics become the main route to a prescription, demand can be steered toward patients with the greatest medical need, which matters if supply is tight or if public money is involved. If pharmacies fill any valid prescription, uptake could move faster than the support services can follow. The ministry has not yet said which of these models it intends to use.

What to watch next

The first marker is product detail: which body approved Ozempic, for which uses, and when the first stock reaches pharmacy shelves. The second is the list of other branded obesity medicines under review. Tufton did not name them, and the best known brands worldwide come from Novo Nordisk and Eli Lilly, but the report did not say whether either company has filed in Jamaica. The third is the generic question. Copies of semaglutide are spreading across markets covered by our Americas desk, from Canada to Brazil, and a Jamaican route for them would change prices far more than any single brand launch. The minister's own timeline points to the coming months.

The last marker is money. A decision by the National Health Fund to cover semaglutide, even for a narrow group of patients, would bring the drug within reach of people who cannot pay pharmacy prices, and it would test the public budget. A decision not to cover it would leave access tied to income, which is how the informal market grew in the first place. For Ozempic in Jamaica the approval is a start, not an outcome, because the report offers no price, no supplier and no patient numbers. The next ministry statements, and any notice from the National Health Fund, will show whether cheaper generics arrive within the quarter Tufton described.

Conclusion

Ozempic in Jamaica is now approved for distribution, according to the health minister, with other obesity medicines and cheaper generics expected to follow through pharmacies. The government ties the drugs to a new referral clinic and may extend access through the National Health Fund. Price, supplier, approved uses and dates are still missing, and those details will decide whether legal supply replaces the informal trade.

Why it matters in Jamaica

Jamaicans seeking GLP-1 drugs have relied on an informal trade from abroad at high prices. Legal pharmacy supply, possible National Health Fund support and a referral clinic could bring the drugs into a regulated, traceable channel.

What to watch

Which body approved Ozempic and for which uses, the first pharmacy stock and price, the names of other obesity drugs under review, and any National Health Fund listing.

Sources

  1. The Gleaner: Ozempic approved for local distribution

Spotted a wrong figure? Tell the desk; we fix errors under our corrections policy.

Peptide Global reports news about medicines and markets. Nothing here is medical or investment advice.